• Subjects of both sexes, between 6 months and 16 years of age, Caucasian, in good health, whose parents/tutors provided a written and signed informed consent for participation in the study shall be enrolled. In particular, as regards parents/tutors:

‣ Both parents/tutors, in case of joint custody, must provide a written and signed informed consent for the participation of the child in the study according to the instructions provided by the investigators;

⁃ They must accept to bring the child to the clinical trial facility on predefined visit days according to the instructions provided by the investigators;

⁃ They must be willing and be able to follow the trial requirements provided by the investigators.

∙ The inclusion criteria provide that:

• Symptoms and signs compatible with a clinical diagnosis of Atopic Dermatitis should be present upon enrollment;

• The clinical severity of AD should correspond to an EASI ranging between 1.0 and 21.0 and an IGA equal to 2 or 3;

• Pruritus severity assessed by means of VAS scale ≥ 4 cm should be referred to the part of the body to be treated, as a requirement for inclusion in the study;

• The clinical assessment should envisage for the patient the indication of a moisturizing/emollient treatment as single therapy for AD (in accordance with European Guidelines on AD treatment).